about
HLA-DR-DQ haplotypes and genotypes in Finnish patients with rheumatoid arthritisPhysical activity and bone mineral acquisition in peripubertal girls.Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial.Exercise-induced training effects on bone mineral content: a 7-year follow-up study with adolescent female gymnasts and runners.Does parvovirus B19 have a role in rheumatoid arthritis?Persistence of parvovirus B19 in synovial fluid and bone marrow.Combination DMARD therapy including corticosteroids in early rheumatoid arthritis.Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trOnly high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategyImmunogenetic differences between patients with familial and non-familial rheumatoid arthritis.Differences between female and male patients with familial rheumatoid arthritis.Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up studyPolymorphism at position +896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritisConventional disease-modifying antirheumatic drugs in early arthritis.A nationwide cross-sectional overview of patients with rheumatoid arthritis followed in outpatient specialty clinics in Finland.Association of reduced physical activity and quantitative ultrasound measurements: a 6-year follow-up study of adolescent girls.A mismatch between self-reported physical work load and the HAQ: early identification of rheumatoid arthritis patients at risk for loss of work productivity.Prognosis of 5-year radiographic erosions of the wrist according to early, late, and persistent wrist swelling or tenderness in patients with early rheumatoid arthritis.Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.Septic sacroiliitis.Joint scintigraphy and erosions.Mononuclear cell response to enterobacteria and Gram-positive cell walls of normal intestinal microbiota in early rheumatoid arthritis and other inflammatory arthritides.Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.Long-term real-life experience with rituximab in adult Finnish patients with rheumatoid arthritis refractory or with contraindication to anti-tumor necrosis factor drugs.Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials.Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial.Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial.Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis.Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).[The goal for the treatment of rheumatoid arthritis should be remission].Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial.Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis.Remission as the treatment goal--the FIN-RACo trial.Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease modifying antirheumatic drugs.Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium.Intestinal anaerobic bacteria in early rheumatoid arthritis (RA).Follow-up study of the effect of a three-month course of ciprofloxacin on the late prognosis of reactive arthritis.
P50
Q24673789-0D8A4D6B-A880-4D50-9E5D-A4DD3B61457AQ30886134-C2A3CE5F-2AE6-4F8A-9FA2-F2EC87177D19Q31019080-F87E0493-44EB-4FA4-8EA5-284369AD3E6EQ33320207-63461C11-C038-4050-8FD0-75DAF48C7658Q33566098-991C6974-4F7D-48FE-B42D-3DA64EB98DACQ33578180-1BBDF9A0-8867-4431-A846-E8FC181A6982Q33789189-E8B724C1-E526-462D-BB1B-C2FB8F555CFEQ34027654-9E5646B2-929E-4312-856C-BBCB4DF3C742Q35548151-F2B60F49-6D08-4E9B-8CEB-D7DEF2444103Q35549170-2E198096-91F0-439A-A8B5-F323C08B7BB3Q35550316-4E585DFB-BE54-458D-BBD6-56C42B645B98Q35554634-301C0B36-44BB-4017-A32F-56BA9C6E918FQ35637930-6CD276DF-3588-4E5F-AB6B-7AB7E8ABD6F1Q36312928-CCA6E986-818E-4306-A25E-30A5991F3FD0Q38198117-2D6B8010-929F-429A-8558-EE08462DE124Q39386268-618C6CF3-805C-4AC6-8FD6-29FAA20F54B3Q39962973-B1DDB158-048C-4236-B4DA-67D841AAA669Q40252625-F15469B6-0C4F-4107-A318-C4E6C2A48FBEQ40455661-1EC28ED8-DB29-481B-B61A-8C6CFDA989FDQ40835898-7183C266-C9E6-4276-82E2-4539292FDF09Q41157155-5B9F47CF-5C5B-486C-A5F4-46B4780BB6A2Q41471740-DB8E20CA-D4EE-4973-87DF-8CBC36072E5AQ41523077-E324EA10-7049-4CF2-AB70-02379E384520Q41651531-BBA0E81E-4429-4568-94A0-458A7811A176Q41914321-8B46F000-90A4-44BF-A514-B7B00170610EQ41914447-339E5EE9-E620-4EB9-AF61-F2F995A8DB09Q41914699-39F789D3-7ADC-4F98-AA83-C0E4C5961E90Q41917701-7FF24DF2-4884-4FD5-B1E0-46CF139777C7Q41927010-45D0F8D7-FBBE-433E-89E9-4B992F50116AQ41928100-F41DC112-DB9D-4BB3-A56E-633474EAA462Q41929058-56173D66-D5FB-4021-9288-B8ACA4DE8C39Q41935481-3AD3190B-1584-43FA-A354-4AFB793220B1Q41936237-CE8F9A28-64CC-4193-B42E-5BCCED0432E9Q41943871-243535A9-657D-4BC5-8AAB-ACD151836240Q41944270-C4549D94-C8E4-4410-8D21-9E8B9D547DC3Q44183027-21DA6DEE-B1FC-410B-8C8F-FDAA6D0BEE03Q44493225-4F084932-9F15-4E27-9935-8AAC5178D556Q44652565-8FBEAE33-CCFA-4618-8214-0E8E1C73BD0FQ46509727-C2B8058C-5BD3-41DA-B2A1-5D15D17AD6F4Q46512339-4F3C6C2F-4D96-400C-B898-AA5FAB127112
P50
description
researcher ORCID ID = 0000-0003-1273-4805
@en
wetenschapper
@nl
name
Timo Möttönen
@ast
Timo Möttönen
@en
Timo Möttönen
@nl
type
label
Timo Möttönen
@ast
Timo Möttönen
@en
Timo Möttönen
@nl
prefLabel
Timo Möttönen
@ast
Timo Möttönen
@en
Timo Möttönen
@nl
P31
P496
0000-0003-1273-4805